Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide effects on vascular inflammation and hematopoietic stem cells in type 2 diabetes
NL-OMON53529Completed
- Sponsor
- Amsterdam University Medical Center
- Start
- Jan 2023
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Open-label, single-arm trial of semaglutide in type 2 diabetes mellitus (T2DM), sponsored by Amsterdam University Medical Center. Primary endpoints: Change in coronary 68Ga-Dotatate uptake after semaglutide and Correlation of bone marrow HSPC phenotype and function with inflammatory imaging. Started Jan 2023; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON53529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53529.